Empowered Funds’s BioMarin Pharmaceuticals BMRN Stock Holding History

Empowered Funds’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.25M	Buy	39,267 +6,064	+18%	+$332K	0.01%	1125
2026 Q1	$1.88M	Buy	33,203 +3,776	+13%	+$220K	0.01%	1142
2025 Q4	$1.75M	Sell	29,427 -122,669	-81%	-$6.68M	0.03%	520
2025 Q3	$8.24M	Buy	152,096 +142,595	+1,501%	+$8.15M	0.08%	301
2025 Q2	$522K	Sell	9,501 -2,522	-21%	-$149K	0.01%	1300
2025 Q1	$850K	Buy	12,023 +8,112	+207%	+$546K	0.01%	1054
2024 Q4	$257K	Buy	+3,911	New	+$262K	﹤0.01%	1429
2024 Q3	–	Sell	-2,677	Closed	-$220K	–	1400
2024 Q2	$220K	Buy	2,677 +294	+12%	+$24.5K	﹤0.01%	1275
2024 Q1	$208K	Buy	+2,383	New	+$213K	﹤0.01%	1296

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Empowered Funds's BMRN Position: Q2 2026 in Review

Empowered Funds increased its BioMarin Pharmaceuticals (BMRN) stake by 18% in Q2 2026, buying an estimated $332K and bringing the position to 39,267 shares worth $2.25M. The position accounts for 0.01% of the portfolio, ranked #1125.

Empowered Funds first reported a position in BMRN in Q1 2024 and has held it in 9 quarters since. The position peaked at $8.24M in Q3 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Empowered Funds held 39,267 shares of BioMarin Pharmaceuticals worth $2.25M as of Q2 2026.
Empowered Funds bought 6,064 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $332K.
BioMarin Pharmaceuticals made up 0.01% of Empowered Funds's portfolio in Q2 2026, its #1125 holding.
Empowered Funds first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Empowered Funds's BioMarin Pharmaceuticals position peaked at $8.24M in Q3 2025.
564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.